171 related articles for article (PubMed ID: 35708458)
1. A Case of Sterile Corneal Stromal Infiltration with Hypotonic Maculopathy Under Brimonidine Treatment.
Vidal Oliver L; Díaz Barrón A; López Montero A; Gil-Hernández I; Duch Samper AM
Ocul Immunol Inflamm; 2023 Oct; 31(8):1716-1719. PubMed ID: 35708458
[TBL] [Abstract][Full Text] [Related]
2. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
Manabe Y; Sawada A; Mochizuki K
Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
[TBL] [Abstract][Full Text] [Related]
3. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
4. Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine.
Clemente-Tomás R; Arciniegas-Perasso CA; Hervás-Hernandis JM; García-Ibor F; Ruiz-Del Río N; Duch-Samper AM
Arch Soc Esp Oftalmol (Engl Ed); 2018 Oct; 93(10):511-514. PubMed ID: 29910082
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine tartrate for the treatment of glaucoma.
Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine-associated uveitis - a descriptive case series.
Hopf S; Mercieca K; Pfeiffer N; Prokosch-Willing V
BMC Ophthalmol; 2020 Dec; 20(1):489. PubMed ID: 33334316
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Kim KE; Lee CK; Shin J; Kim Y; Rho S
Sci Rep; 2023 Apr; 13(1):5700. PubMed ID: 37029145
[TBL] [Abstract][Full Text] [Related]
8. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
9. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
10. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
11. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
12. Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H; Yamamoto T; Aihara M; Koizumi N; Minami H; Kojima S; Isobe T; Kanazawa M; Suganami H;
Adv Ther; 2023 Aug; 40(8):3559-3573. PubMed ID: 37330927
[TBL] [Abstract][Full Text] [Related]
13. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
14. Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono C
Cornea; 2017 Dec; 36(12):1567-1569. PubMed ID: 28938378
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
18. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
19. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]